These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32285259)

  • 41. PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis.
    Carrera CG; Dapavo P; Malagoli P; Naldi L; Arancio L; Gaiani F; Egan CG; Di Mercurio M; Cattaneo A
    J Dermatolog Treat; 2018 Aug; 29(5):481-486. PubMed ID: 29058948
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial.
    Kavanaugh A; Puig L; Gottlieb AB; Ritchlin C; Li S; Wang Y; Mendelsohn AM; Song M; Zhu Y; Rahman P; McInnes IB;
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1739-49. PubMed ID: 26097039
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
    Woolacott N; Bravo Vergel Y; Hawkins N; Kainth A; Khadjesari Z; Misso K; Light K; Asseburg C; Palmer S; Claxton K; Bruce I; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
    [TBL] [Abstract][Full Text] [Related]  

  • 44. International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis.
    Chandran V; Gottlieb A; Cook RJ; Duffin KC; Garg A; Helliwell P; Kavanaugh A; Krueger GG; Langley RG; Lynde C; McHugh N; Mease P; Olivieri I; Rahman P; Rosen CF; Salvarani C; Thaci D; Toloza SM; Wong MY; Zhou QM; Gladman DD
    Arthritis Rheum; 2009 Sep; 61(9):1235-42. PubMed ID: 19714610
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Real-World Retention and Clinical Effectiveness of Secukinumab for Psoriatic Arthritis: Results From the Canadian Spondyloarthritis Research Network.
    Gladman DD; Choquette D; Khraishi M; Inman RD; Hussein S; Neish D; Leclerc P
    J Rheumatol; 2023 May; 50(5):641-648. PubMed ID: 36521913
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of antidrug antibodies in ustekinumab therapy and the impact of methotrexate.
    Mojtahed Poor S; Henke M; Ulshöfer T; Köhm M; Behrens F; Burkhardt H; Schiffmann S
    Rheumatology (Oxford); 2023 Dec; 62(12):3993-3999. PubMed ID: 37079726
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study.
    Bongartz T; Coras B; Vogt T; Schölmerich J; Müller-Ladner U
    Rheumatology (Oxford); 2005 Jan; 44(1):126-9. PubMed ID: 15479756
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Drug survival of secukinumab, ustekinumab, and certolizumab pegol in psoriasis: a 2-year, monocentric, retrospective study.
    Chatzimichail G; Günther J; Ständer S; Thaçi D
    J Dermatolog Treat; 2022 May; 33(3):1749-1753. PubMed ID: 33430676
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA.
    Brahe CH; Ørnbjerg LM; Jacobsson L; Nissen MJ; Kristianslund EK; Mann H; Santos MJ; Reino JG; Nordström D; Rotar Z; Gudbjornsson B; Onen F; Codreanu C; Lindström U; Möller B; Kvien TK; Pavelka K; Barcelos A; Sánchez-Piedra C; Eklund KK; Tomšič M; Love TJ; Can G; Ionescu R; Loft AG; van der Horst-Bruinsma IE; Macfarlane GJ; Iannone F; Hyldstrup LH; Krogh NS; Østergaard M; Hetland ML
    Rheumatology (Oxford); 2020 Jul; 59(7):1640-1650. PubMed ID: 31665497
    [TBL] [Abstract][Full Text] [Related]  

  • 50. How effective is ustekinumab in controlling psoriatic arthritis?
    Bonifati C; Graceffa D
    Dermatol Ther; 2016 May; 29(3):155-9. PubMed ID: 26626908
    [TBL] [Abstract][Full Text] [Related]  

  • 51. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
    Tobin AM; Kirby B
    BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs.
    Ghosh S; Gensler LS; Yang Z; Gasink C; Chakravarty SD; Farahi K; Ramachandran P; Ott E; Strober BE
    Drug Saf; 2019 Jun; 42(6):751-768. PubMed ID: 30739254
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A retrospective, observational multicenter study of 141 patients treated with ustekinumab 90 mg.
    Llamas-Velasco M; Baniandrés O; Rivera R; Reymundo Jimenez A; Hospital M; García Zamora E; González-Cantero Á; Andrés Lencina JJ; Daudén E; de la Cueva P
    Dermatol Ther; 2020 Jul; 33(4):e13678. PubMed ID: 32447810
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reduced joint counts misclassify patients with oligoarticular psoriatic arthritis and miss significant numbers of patients with active disease.
    Coates LC; FitzGerald O; Gladman DD; McHugh N; Mease P; Strand V; Helliwell PS
    Arthritis Rheum; 2013 Jun; 65(6):1504-9. PubMed ID: 23529837
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative Effectiveness of Ustekinumab Versus Adalimumab in Induction of Clinical Response and Remission in Crohn's Disease: Experience of a Real-World Cohort at a Tertiary Care Inflammatory Bowel Disease Referral Center.
    Ahmed Z; Venkata K; Zhang N; Malik TA
    Gastroenterology Res; 2019 Oct; 12(5):245-251. PubMed ID: 31636774
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Patient reported health outcomes and non-adherence in psoriasis patients receiving adalimumab or ustekinumab for moderate to severe plaque psoriasis.
    Goren A; Carter C; Lee S
    J Dermatolog Treat; 2016; 27(1):43-50. PubMed ID: 26088404
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials.
    Helliwell PS; Gladman DD; Chakravarty SD; Kafka S; Karyekar CS; You Y; Campbell K; Sweet K; Kavanaugh A; Gensler LS
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32209721
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis.
    Mugheddu C; Atzori L; Del Piano M; Lappi A; Pau M; Murgia S; Zucca I; Rongioletti F
    Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28833973
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Attainment of Minimal Disease Activity Using Methotrexate in Psoriatic Arthritis.
    Sheane BJ; Thavaneswaran A; Gladman DD; Chandran V
    J Rheumatol; 2016 Sep; 43(9):1718-23. PubMed ID: 27422895
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis.
    Hayashi M; Umezawa Y; Fukuchi O; Ito T; Saeki H; Nakagawa H
    J Dermatol; 2014 Nov; 41(11):974-80. PubMed ID: 25346301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.